Nautilus Biotechnology regains Nasdaq $1.00 bid-price compliance

Nautilus Biotechnology (NAUT) regained Nasdaq listing compliance.

Rhea-AI Filing Summary

Nautilus Biotechnology (NAUT) regained Nasdaq listing compliance. The company received notice on November 3, 2025 that it meets Nasdaq Listing Rule 5550(a)(2) after its common stock closed at or above $1.00 per share for a minimum of ten consecutive business days. Nasdaq stated the matter is now closed.

Earlier in 2025, NAUT had fallen below the minimum bid-price requirement and was granted compliance periods through October 28, 2025, then transferred to The Nasdaq Capital Market on October 29, 2025 with additional time to cure. Regaining compliance supports the company’s continued listing on The Nasdaq Capital Market under the NAUT ticker.

Insights

Listing & Exchanges Analyst

Compliance restored; continued Nasdaq listing preserved.

Nautilus Biotechnology confirmed compliance with Nasdaq’s minimum bid-price rule after maintaining closes at or above $1.00 for at least ten consecutive business days. Nasdaq indicated the compliance matter is closed, which supports ongoing trading on The Nasdaq Capital Market.

This follows a prior deficiency notice tied to sub-$1.00 bids and a market transfer on October 29, 2025. While operational performance isn’t addressed here, maintaining listing status avoids the administrative and liquidity challenges associated with potential delisting.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nautilus Biotechnology (NAUT) announce?

NAUT received notice on November 3, 2025 that it regained compliance with Nasdaq’s minimum bid-price rule after meeting the requirement for a minimum of ten consecutive business days.

Which Nasdaq rule did NAUT satisfy to regain compliance?

Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market.

What triggered the earlier compliance period for NAUT?

A prior notice based on a 30 consecutive business day period ending April 30, 2025, during which the bid price was below $1.00 per share.

On which market is NAUT currently listed?

The Nasdaq Capital Market, under the ticker NAUT.

What is the status of the Nasdaq compliance matter now?

Nasdaq informed NAUT that the matter is closed after the company met the minimum bid-price requirement.

Did NAUT receive additional time to regain compliance in 2025?

Yes. After an initial period through October 28, 2025, NAUT transferred on October 29, 2025 to The Nasdaq Capital Market and was afforded a second 180-day compliance period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/03/2025 - 05:32 PM Learn about SEC filing dates

0001808805FALSE00018088052025-11-032025-11-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2025

NAUTILUS BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39434

98-1541723

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

2701 Eastlake Avenue East Seattle, Washington (Address of principal executive offices) 98102 (Zip code)

(206) 333-2001

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

NAUT

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

Item 8.01. Other Events

On November 3, 2025, Nautilus Biotechnology, Inc. (the “Company”) received a written notice from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq’s Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock had met or exceeded $1.00 per share for a minimum of ten consecutive business days and that the matter is now closed.

As previously disclosed in a current report on Form 8-K filed with the Securities and Exchange Commission on May 2, 2025, the Company received a letter from the Staff indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between March 19, 2025, through April 30, 2025, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). Pursuant to Listing Rule 5810(c)(3)(A), the Company was granted 180 calendar days, or until October 28, 2025, to regain compliance with the Minimum Bid Price Requirement. Subsequently, on October 29, 2025, the Company transferred to The Nasdaq Capital Market and was afforded the remainder of The Nasdaq Capital Market’s second 180 calendar day compliance period, or until April 27, 2026, to regain compliance with the Minimum Bid Price Requirement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 4, 2025

			NAUTILUS BIOTECHNOLOGY, INC.
			By:			/s/ Sujal Patel
			Name:			Sujal Patel
			Title:			Chief Executive Officer